Raptiva in Palm and Sole Psoriasis

• Sponsor: Merck KGaA, Darmstadt, Germany (Industry)
• Overall Status: Terminated
• CT.gov ID: NCT00972543
• Collaborator: (none)
• Enrollment: 6
• Arms: 2

Study Details

Study Description

Brief Summary

The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or soles scoring Palmo-plantar Pustular Psoriasis Area and Severity Index (PPPASI) ≥5 in subjects that are candidates for phototherapy or systemic therapies.

The rational of the trial is that psoriasis involving palms and/or soles is a painful condition associated with fissuring, scaling and in some instances with pustulation. Because of its localization, it is a disabling condition that limits dexterity and affects social interaction, leading to compromised quality of life; and this confers additional severity to that of plaque psoriasis on the body. The therapeutic approach for palm and sole plaque-type psoriasis usually begins with topical corticosteroid treatment. If the disease reaches a certain extent, the next step involves the addition of systemic treatments. Substances like methotrexate, retinoids and cyclosporine have shown to be efficacious, but their long-term usage is often limited by toxicity. Biologic treatments for psoriasis avoid this toxicity and offer a new therapeutic approach.

The therapeutic potential of Raptiva® to treat palm and sole psoriasis refractory to systemic treatments has been described in numerous case reports and in one placebo-controlled phase IV study. However, in all cases, the number of subjects included was low, and in most cases the trials were not prospectively designed.

Since the efficacy of Raptiva® on psoriasis of palms and soles must be determined using the validated PPPASI measure, it is necessary for scientific and ethical reasons to include a placebo arm during the first 12 weeks. Finally, as the clinical response may sometimes take longer than 12 weeks, subjects must be treated and evaluated during an additional 12-week open-label extended treatment period.

Condition or Disease	Intervention/Treatment	Phase
Chronic Plaque Psoriasis	Biological: Efalizumab (Raptiva); Biological: Placebo	Phase 4

Study Design

• Study Type: Interventional
• Actual Enrollment: 6 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Primary Purpose: Treatment
• Official Title: A Phase IV Multicentre, Randomized Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Raptiva in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis Involving Palms and/or Soles, With or Without Pustules.
• Study Start Date: Sep 1, 2008
• Actual Primary Completion Date: May 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Raptiva Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Biological: Efalizumab (Raptiva); Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.; Other Names: Raptiva
Placebo Comparator: Placebo Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Biological: Placebo; Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.

Outcome Measures

Primary Outcome Measures

1. Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) [Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

   Minimum possible score 0, maximum possible score 72.

2. Static Physician Global Assessment Hands and Feet (sPGA - H&F) [Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20 visits and Early Termination Visit]

   Minimum possible score 0, maximum possible score 4.

3. Psoriasis Area and Severity Index (PASI) [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

   Minimum possible score 0, maximum possible score 72.

4. Static Physician Global Assessment (SPGA) [Measured at Screening, Day 0 and Day 7]

   The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse

5. Dynamic Physician's Global Assessment of Change (dPGA) [Measured at Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

   The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse

Secondary Outcome Measures

1. Participants With Direct Physical Examination Abnormalities [Measured at at screening, Day 0, Week 4, Week 12, and Early Termination visits]

   Physical examination included Lymph node palpation, Abdominal palpation, Auscultation of the lung, heart and intestinum

2. Complaint Directed Physical Examinations [Measure at (Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits)]

   Number of participants undergoing complaint directed physical examinations

3. Heart Rate [Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits]

4. Arterial Blood Pressure [Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits]

5. Temperature [Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits]

6. Weight Measurements [Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

7. Haematology Laboratory Assessments - Haemoglobin [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

   Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

8. Haematology Laboratory Assessments - Haematocrit [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

   Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

9. Haematology Laboratory Assessments - Red Cell Count [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

   Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

10. Haematology Laboratory Assessments - White Cell Count [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

11. Haematology Laboratory Assessments - Platelets [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

12. Haematology Laboratory Assessments - Neutrophils [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

13. Haematology Laboratory Assessments - Lymphocytes [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

14. Haematology Laboratory Assessments - Monocytes [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

15. Haematology Laboratory Assessments - Eosinophils [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

16. Haematology Laboratory Assessments - Basophils [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

17. Clinical Chemistry Laboratory Assessments - Sodium [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

18. Clinical Chemistry Laboratory Assessments - Potassium [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

19. Clinical Chemistry Laboratory Assessments - Urea [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

20. Clinical Chemistry Laboratory Assessments - Creatinine [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

21. Clinical Chemistry Laboratory Assessments - Total Bilirubin [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

22. Clinical Chemistry Laboratory Assessments - Total Protein [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

23. Clinical Chemistry Laboratory Assessments - Calcium [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

24. Clinical Chemistry Laboratory Assessments - Aspartate Transaminase [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

25. Clinical Chemistry Laboratory Assessments - Alanine Transaminase [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

26. Clinical Chemistry Laboratory Assessments - Gamma Glutamyl Transpeptidase [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

27. Clinical Chemistry Laboratory Assessments - Alkaline Phosphatase [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

28. Clinical Chemistry Laboratory Assessments - C Reactive Protein [Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits]

    Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.

29. Negative Serum Human Chorionic Gonadotrophin (hCG) Pregnancy Test [Measured at screening (Day -14 to Day -1)]

    A serum human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.

30. Negative Urinary Human Chorionic Gonadotrophin (hCG) Pregnancy Test [Measured at screening (Day -14 to Day -1)]

    A urinary human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

To be eligible for inclusion into this trial, the subjects must fulfill all of the following criteria:

1. Subjects must have moderate to severe chronic (disease history of at least 6 months from diagnosis) plaque psoriasis involving the palms and/or soles (PPPASI =/>5) at screening, and must be candidates for phototherapy and systemic therapies.

2. Subjects must be outpatients.

3. Subjects must have stable disease at study entry (i.e. no exacerbation of psoriasis during the screening period).

4. Subjects must not have received any systemic psoriasis medication at least 14 days prior to the first administration of investigational medicinal product.

5. Subjects must not have received any topical psoriasis medication at least 14 days prior to the first administration of investigational medicinal product (emollients are allowed, as well as low potency steroids to the face and/or groin).

6. Subjects must be at least 18 years old at the time that the informed consent is obtained.

7. Female subjects of childbearing potential must use an adequate method of contraception to prevent pregnancy and must agree to continue to practice adequate contraception for the duration of their participation in the study (up to the last safety follow up visit). For male subjects, it is mandatory to practice birth control during participation in the trial, as there are no data on the effect of Raptiva® on spermatogenesis. For the purposes of this trial, women of childbearing potential are defined as "All female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive." Adequate contraception is defined as two barrier methods, or one barrier method with spermicide, or an intrauterine device or use of the oral female contraceptive.

8. Subjects must have discontinued all biological agents at least 3 months prior to the first study treatment injection.

9. Subjects must have discontinued any investigational drug or treatment at least 3 months prior to study Day 0 and/or as per washout requirements from previous protocol.

10. Subjects must be willing and able to comply with the protocol requirements for the duration of the study.

11. Subjects must have provided their written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent

Exclusion Criteria:

To be eligible for inclusion in this trial, the subjects must not meet any of the following criteria:

1. Hypersensitivity to Raptiva®/matching placebo or to any of their excipients.

2. Current use of any prohibited therapy (systemic or topical treatments for psoriasis, such as retinoids; immunosuppressive drugs such as methotrexate, cyclosporine A, azathioprine, or mycophenolate mofetil, or any other experimental drug).

3. Previous or current exposure to Raptiva®.

4. History of or ongoing alcohol or drug abuse.

5. History of or ongoing opportunistic infection or other serious infection. This includes any infections from the following list: Pneumocystis carinii, cytomegalovirus organ infections, Candida albicans (excluding simple localised muco-cutaneous infections), mycobacterium infections, Cryptococcus neoformans, Toxoplasma gondii, herpes simplex (excluding localised oral or genital muco-cutaneous infection), herpes zoster (excluding simple shingle eruption), cryptosporidium, Isospora belli, coccidioidomycosis, aspergillosis, histoplasmosis, and nocardiosis. This also includes diagnoses requiring more than 2 weeks of therapy, such as endocarditis and osteomyelitis treated in the past 6 months. In addition, if the subject is currently receiving antibiotics, antivirals, or antifungals for an infection or for suppression of or prophylaxis for any diagnosis, the subject will be excluded.

6. Seropositivity for hepatitis B antigen, hepatitis C antibody, or human immunodeficiency virus (HIV). Subjects will undergo testing during screening; any subjects who are found to be seropositive for hepatitis B antigen, hepatitis C antibody, or HIV will be excluded, and proper diagnosis and further therapy will be recommended.

7. Presence of active tuberculosis.

8. Presence or history of malignancy including lymphoproliferative disorders.

9. Pregnancy or breast-feeding.

10. History of hepatic cirrhosis, regardless of cause or severity.

11. History or presence of thrombocytopenia, haemolytic anaemia, clinically significant anaemia, a white blood cell count <4,000 cells/μL or >14,000 cells/μL, a haematocrit (HCT) <30%, a haemoglobin (Hgb) level <11 g/dL, or a platelet count <150,000 cells/μL.

12. Hepatic enzyme levels =/>3 times the upper limit of normal or serum creatinine level =/>2 times the upper limit of normal.

13. Vaccination with a live or live-attenuated vaccine within the 14 days prior to the first dose of investigational medicinal product.

14. Any medical condition that, in the judgment of the Investigator, would jeopardise the subject's safety following exposure to investigational medicinal product (Raptiva® or placebo equivalent) or would significantly interfere with the subject's ability to comply with the provisions of this protocol.

15. Other specific forms of psoriasis like guttate, erythrodermic or pustular psoriasis as sole or predominant form of psoriasis.

16. Immunodeficiencies.

17. Signs and symptoms suggestive of transmissible spongiform encephalopathy or family history of such.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Merck KGaA, Darmstadt, Germany

Investigators

• Study Director: Nicole Selenko-Gebauer, MD, Merck Serono S.A., Geneva

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Merck KGaA, Darmstadt, Germany
• ClinicalTrials.gov Identifier: NCT00972543
• Other Study ID Numbers: 28861
• First Posted: Sep 7, 2009
• Last Update Posted: Feb 13, 2014
• Last Verified: Jan 1, 2014

• Keywords provided by Merck KGaA, Darmstadt, Germany: Moderate to severe chronic plaque psoriasis; palms and/or soles; with or without pustules
• Additional relevant MeSH terms: Psoriasis; Antibodies, Monoclonal

Study Results

Participant Flow

Recruitment Details	Date of first subject's first visit: 29 Sep 2008 Date of last subject's last visit: 25 May 2009 Subjects were screened at 3 centers in Australia, of which 2 centers enrolled subjects. It was planned to conduct the trial in centers in Australia and Latin America; however, the trial was terminated before most centers were initiated.
Pre-assignment Detail	Screening was performed within 2 weeks prior to starting trial treatment.

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Period Title: Overall Study
STARTED	5	1
COMPLETED	0	0
NOT COMPLETED	5	1

Baseline Characteristics

Arm/Group Title	Raptiva	Placebo	Total
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Total of all reporting groups
Overall Participants	5	1	6
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	5 100%	1 100%	6 100%
>=65 years	0 0%	0 0%	0 0%
Sex: Female, Male (Count of Participants)
Female	2 40%	0 0%	2 33.3%
Male	3 60%	1 100%	4 66.7%
Region of Enrollment (participants) [Number]
Australia	5 100%	1 100%	6 100%
Negative Serum Pregnancy Test (participants) [Number]
Negative test	1 20%	0 0%	1 16.7%
Not tested (Male or surgically sterile female)	4 80%	1 100%	5 83.3%
Negative Urinary Pregnancy Test (participants) [Number]
Negative test	1 20%	0 0%	1 16.7%
Not tested (Male or surgically sterile female)	4 80%	1 100%	5 83.3%

Outcome Measures

1. Primary Outcome

Title	Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)
Description	Minimum possible score 0, maximum possible score 72.
Time Frame	Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

2. Primary Outcome

Title	Static Physician Global Assessment Hands and Feet (sPGA - H&F)
Description	Minimum possible score 0, maximum possible score 4.
Time Frame	Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20 visits and Early Termination Visit

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

3. Primary Outcome

Title	Psoriasis Area and Severity Index (PASI)
Description	Minimum possible score 0, maximum possible score 72.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

4. Primary Outcome

Title	Static Physician Global Assessment (SPGA)
Description	The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse
Time Frame	Measured at Screening, Day 0 and Day 7

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

5. Primary Outcome

Title	Dynamic Physician's Global Assessment of Change (dPGA)
Description	The global response of all psoriatic lesions to therapy compared with the baseline condition using Study Day 0 Body Diagrams will be evaluated using the following categories: Cleared (100% improvement), Excellent (75-99 improvement), Good (50-74% improvement), Fair (25-49% improvement), Slight (1-24% improvement), Unchanged, or Worse
Time Frame	Measured at Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

6. Secondary Outcome

Title	Participants With Direct Physical Examination Abnormalities
Description	Physical examination included Lymph node palpation, Abdominal palpation, Auscultation of the lung, heart and intestinum
Time Frame	Measured at at screening, Day 0, Week 4, Week 12, and Early Termination visits

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

7. Secondary Outcome

Title	Complaint Directed Physical Examinations
Description	Number of participants undergoing complaint directed physical examinations
Time Frame	Measure at (Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits)

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

8. Secondary Outcome

Title	Heart Rate
Time Frame	Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

9. Secondary Outcome

Title	Arterial Blood Pressure
Time Frame	Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

10. Secondary Outcome

Title	Temperature
Time Frame	Measure at Day 0, Day 7, Week 8, Week 16 and Follow Up and Early Termination visits

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

11. Secondary Outcome

Title	Weight Measurements
Time Frame	Measured at Screening, Day 0, Day 7, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

Results not analysed due to early termination of the study

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	0	0

12. Secondary Outcome

Title	Haematology Laboratory Assessments - Haemoglobin
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

13. Secondary Outcome

Title	Haematology Laboratory Assessments - Haematocrit
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

14. Secondary Outcome

Title	Haematology Laboratory Assessments - Red Cell Count
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

15. Secondary Outcome

Title	Haematology Laboratory Assessments - White Cell Count
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

16. Secondary Outcome

Title	Haematology Laboratory Assessments - Platelets
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

17. Secondary Outcome

Title	Haematology Laboratory Assessments - Neutrophils
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

18. Secondary Outcome

Title	Haematology Laboratory Assessments - Lymphocytes
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

19. Secondary Outcome

Title	Haematology Laboratory Assessments - Monocytes
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

20. Secondary Outcome

Title	Haematology Laboratory Assessments - Eosinophils
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

21. Secondary Outcome

Title	Haematology Laboratory Assessments - Basophils
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

22. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Sodium
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

23. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Potassium
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

24. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Urea
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

25. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Creatinine
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

26. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Total Bilirubin
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

27. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Total Protein
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

28. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Calcium
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

29. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Aspartate Transaminase
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

30. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Alanine Transaminase
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

31. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Gamma Glutamyl Transpeptidase
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

32. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - Alkaline Phosphatase
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

33. Secondary Outcome

Title	Clinical Chemistry Laboratory Assessments - C Reactive Protein
Description	Participants with abnormal laboratory values considered by the Investigator to be clinically significant reported as adverse events.
Time Frame	Measured at Screening, Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, and Early Termination visits

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Subjects without values reported as adverse events	5 100%	1 100%
Subjects with values reported as adverse events	0 0%	0 0%

34. Secondary Outcome

Title	Negative Serum Human Chorionic Gonadotrophin (hCG) Pregnancy Test
Description	A serum human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.
Time Frame	Measured at screening (Day -14 to Day -1)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Negative test	1 20%	0 0%
Not tested (Male or surgically sterile female)	4 80%	1 100%

35. Secondary Outcome

Title	Negative Urinary Human Chorionic Gonadotrophin (hCG) Pregnancy Test
Description	A urinary human chorionic gonadotrophin (hCG) pregnancy test will be conducted for all female subjects of childbearing potential prior to entering the study.
Time Frame	Measured at screening (Day -14 to Day -1)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Raptiva	Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks	Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
Measure Participants	5	1
Negative test	1 20%	0 0%
Not tested (Male or surgically sterile female)	4 80%	1 100%

Adverse Events

Time Frame	Up to 32 weeks
Arm/Group Title	Raptiva		Placebo
Arm/Group Description	Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks		Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
All Cause Mortality
	Raptiva		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Raptiva		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/5 (40%)		0/1 (0%)
Infections and infestations
Meningitis aseptic	1/5 (20%)	1	0/1 (0%)	0
Osteomyelitis	1/5 (20%)	1	0/1 (0%)	0
Other (Not Including Serious) Adverse Events
	Raptiva		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	5/5 (100%)		1/1 (100%)
Eye disorders
Left eye redness	1/5 (20%)	1	0/1 (0%)	0
Gastrointestinal disorders
Nausea	1/5 (20%)	3	0/1 (0%)	0
General disorders
Generalized body ache	1/5 (20%)	1	0/1 (0%)	0
Swelling of left heel	1/5 (20%)	1	0/1 (0%)	0
Flu-like symptoms	0/5 (0%)	0	1/1 (100%)	2
Infections and infestations
Flu-like symptoms	1/5 (20%)	1	0/1 (0%)	0
Upper respiratory tract infection	1/5 (20%)	3	0/1 (0%)	0
Folliculitis of groin	1/5 (20%)	1	0/1 (0%)	0
Secondary infection, both feet	1/5 (20%)	1	0/1 (0%)	0
Viral upper respiratory tract infection	1/5 (20%)	1	0/1 (0%)	0
Infected right foot	1/5 (20%)	1	0/1 (0%)	0
Ear infection	1/5 (20%)	1	0/1 (0%)	0
Cellulitis right leg	1/5 (20%)	1	0/1 (0%)	0
Musculoskeletal and connective tissue disorders
Bilateral arm aches (nonspecific)	0/5 (0%)	0	1/1 (100%)	1
Nervous system disorders
Headache	2/5 (40%)	6	0/1 (0%)	0
Psychiatric disorders
Anxiety attack	1/5 (20%)	1	0/1 (0%)	0
Renal and urinary disorders
Dysuria	1/5 (20%)	1	0/1 (0%)	0
Respiratory, thoracic and mediastinal disorders
Sore throat	1/5 (20%)	1	0/1 (0%)	0
Skin and subcutaneous tissue disorders
Intertrigo of groin	1/5 (20%)	1	0/1 (0%)	0
Contact dermatitis, both feet	1/5 (20%)	1	0/1 (0%)	0
Maculopapular rash on body (id reaction)	1/5 (20%)	1	0/1 (0%)	0
Widespread eczematous rash	1/5 (20%)	1	0/1 (0%)	0
Telogen effluvium	1/5 (20%)	1	0/1 (0%)	0
Eczematous rash	1/5 (20%)	1	0/1 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.